EMA Guidance on Trial Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
The impact of COVID-19 on ongoing trials, on opening a new trial site in an existing trial, ongoing recruitment and continued involvement of participants in the trial, or on starting of new trials needs to be considered. Read this EMA Guidance to learn more about managing your clinical trials during this pandemic.
Related Education Resources.
All ResourcesCountdown to Brexit: Can your clinical supply chain pass the Brexit pressure test
Topics: Pharma Industry, Politics
White Paper
Members
EU Clinical Trial Regulation 536/2014
Topic: Regulatory
Position Paper
Members
Nat'l Coronavirus Response - Road Map to Reopening
Topics: Health Care, Strategic Planning
Report
Free
